

Attorney Docket No.: ISPH-0623  
Inventors: Karras and Condon  
Serial No.: 10/033,742  
Filing Date: December 28, 2001  
Page 2

Listing of Claims:

Claim 1 (currently amended): A compound 8 to 50 nucleobases in length targeted to a 5'-untranslated region, a start codon region, a coding region, or a 3'-untranslated region of a nucleic acid molecule encoding macrophage inflammatory protein 3-alpha (SEQ ID NO: 3), wherein said antisense oligonucleotide specifically hybridizes with ~~said nucleic acid molecule encoding macrophage inflammatory protein 3-alpha~~ one of said regions and inhibits the expression of macrophage inflammatory protein 3-alpha.

Claim 2 (original): The compound of claim 1 which is an antisense oligonucleotide.

Claim 3 (canceled)

Claim 4 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claim 5 (original): The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Attorney Docket No.: **ISPH-0623**  
Inventors: **Karras and Condon**  
Serial No.: **10/033,742**  
Filing Date: **December 28, 2001**  
Page 3

Claim 6 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 7 (original): The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

Claim 8 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9 (original): The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

Claim 10 (original): The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 11 (canceled)

Claim 12 (original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Attorney Docket No.: ISPH-0623  
Inventors: Karras and Condon  
Serial No.: 10/033,742  
Filing Date: December 28, 2001  
Page 4

Claim 13 (original): The composition of claim 12 further comprising a colloidal dispersion system.

Claim 14 (original): The composition of claim 12 wherein the compound is an antisense oligonucleotide.

Claims 15-20 (canceled)